Anti-Fc-Receptor Therapy of Refractory Immune Thrombocytopenic Purpura

S. Ray Mitchell, Gail Whalen, Thomas R. Cupps, Paul Katz, Sarah B. Clarkson, James B. Bussel, Robert P. Kimberly, Jay E. Valinsky, Ralph L. Nachman, Jay C. Unkeless

Research output: Contribution to journalLetter

1 Scopus citations

Abstract

To the Editor: The report in the May 8 issue1 on monoclonal antibody therapy for refractory immune thrombocytopenic purpura adds to the observation that polyclonal intravenous gamma globulin decreases the cytotoxic activity, as well as the phenotypic presence, of natural killer (NK) cells in the circulation.2 However, this study failed to consider the phenotypic as well as functional heterogeneity of the NK-cell population. The choice of the monoclonal antibody anti-Leu 7 (HNK-1) as an indicator of the quantitative NK-cell population, as well as a functional parallel of cytotoxic activity, is less than optimal. Anti-Leu 7 is a non-Fc-directed monoclonal antibody.

Original languageEnglish (US)
Pages (from-to)1230-1231
Number of pages2
JournalNew England Journal of Medicine
Volume315
Issue number19
DOIs
StatePublished - Nov 6 1986

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Anti-Fc-Receptor Therapy of Refractory Immune Thrombocytopenic Purpura'. Together they form a unique fingerprint.

  • Cite this

    Mitchell, S. R., Whalen, G., Cupps, T. R., Katz, P., Clarkson, S. B., Bussel, J. B., Kimberly, R. P., Valinsky, J. E., Nachman, R. L., & Unkeless, J. C. (1986). Anti-Fc-Receptor Therapy of Refractory Immune Thrombocytopenic Purpura. New England Journal of Medicine, 315(19), 1230-1231. https://doi.org/10.1056/NEJM198611063151917